Phase Ib Open-Label Study on Safety, Tolerability, and Pharmacokinetics of PIT565 in Rheumatoid Arthritis Patients

The primary objective of this study is to evaluate the **safety**, **tolerability**, and **pharmacokinetics** of PIT565 in participants with **Rheumatoid Arthritis**. This is clinically relevant as it aims to determine the appropriate dosage and potential adverse effects of PIT565, which could inform future therapeutic strategies for managing Rheumatoid Arthritis. No secondary objectives are provided in the available data.

The clinical trial involves a total of **17 participants** diagnosed with **Rheumatoid Arthritis**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The general health status of the participants is not detailed, nor are any lifestyle considerations such as diet, physical activity, or habits. The trial aims to gather data from a diverse group, ensuring representation across different age groups and genders.

The clinical trial is designed as a **phase Ib**, open-label, ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of PIT565 in participants diagnosed with **rheumatoid arthritis**. The trial is scheduled to commence recruitment on July 28, 2025, and is anticipated to conclude by July 30, 2027. The study will involve a series of structured visits, beginning with an inclusion visit, where participants will undergo screening to confirm eligibility based on predefined criteria. This initial visit will ensure that only suitable candidates are enrolled in the trial.

Following the inclusion visit, participants will attend multiple follow-up visits at specified intervals. These visits are crucial for monitoring the participants' response to the investigational product, assessing any adverse events, and ensuring adherence to the study protocol. The trial will culminate in an end-of-study visit, where final assessments will be conducted to gather comprehensive data on the investigational product's effects.

The expected duration of participant involvement will span the entire trial period, from the initial screening to the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial's methodology, including its open-label design, allows for direct observation of the investigational product's effects, providing valuable insights into its potential therapeutic benefits for individuals with rheumatoid arthritis.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on July 28, 2025, with an estimated completion date of July 30, 2027. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints are not detailed in the available data. The trial will adhere to rigorous methodologies typical of Phase 3 studies, ensuring that efficacy is evaluated with precision and scientific rigor. The collection and analysis of efficacy data will be aligned with standard practices for clinical trials of this nature, although specific tools or instruments are not mentioned. The trial's design and execution will focus on generating reliable and valid data to support the evaluation of the investigational product's efficacy.